Humanigen (Humanigen) Scaled Net Operating Assets : -4.72 (As of Mar. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Humanigen Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Humanigen's operating assets for the quarter that ended in Mar. 2023 was $2.02 Mil. Humanigen's operating liabilities for the quarter that ended in Mar. 2023 was $54.84 Mil. Humanigen's Total Assets for the quarter that ended in Dec. 2022 was $11.20 Mil. Therefore, Humanigen's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2023 was -4.72.

Humanigen Scaled Net Operating Assets Historical Data

The historical data trend for Humanigen's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Humanigen Scaled Net Operating Assets Chart

Humanigen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Scaled Net Operating Assets

Get a 7-Day Free Trial

-3.25

-5.82

-42.43

-1.01

-0.80

Humanigen Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Scaled Net Operating Assets	Get a 7-Day Free Trial															-0.97	-1.01	-1.56	-2.19	-4.72

Competitive Comparison of Humanigen's Scaled Net Operating Assets

For the Biotechnology subindustry, Humanigen's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Humanigen's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Humanigen's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Humanigen's Scaled Net Operating Assets falls into.

Humanigen Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Humanigen's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2022 is calculated as

	Scaled Net Operating Assets (SNOA)		(A: Dec. 2022 )
=	(Operating Assets (A: Dec. 2022 )	-	Operating Liabilities (A: Dec. 2022 ))	/	Total Assets (A: Dec. 2021 )
=	(1.04	-	57.96)	/	71.061
=	-0.80

where

	Operating Assets		(A: Dec. 2022 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	11.195	-	10.155
=	1.04

	Operating Liabilities		(A: Dec. 2022 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	57.96	-	0	-	0
=	57.96

Humanigen's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2023 is calculated as

	Scaled Net Operating Assets (SNOA)		(Q: Mar. 2023 )
=	(Operating Assets (Q: Mar. 2023 )	-	Operating Liabilities (Q: Mar. 2023 ))	/	Total Assets (Q: Dec. 2022 )
=	(2.02	-	54.841)	/	11.195
=	-4.72

where

	Operating Assets		(Q: Mar. 2023 )
=	Total Assets	-	Cash, Cash Equivalents, Marketable Securities
=	5.116	-	3.096
=	2.02

	Operating Liabilities		(Q: Mar. 2023 )
=	Total Liabilities	-	Long-Term Debt & Capital Lease Obligation	-	Short-Term Debt & Capital Lease Obligation
=	54.841	-	0	-	0
=	54.841

Humanigen Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Humanigen's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Humanigen (Humanigen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humanigen Inc (OTCPK:HGENQ) » Definitions » Scaled Net Operating Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

830 Morris Turnpike, 4th Floor, Short Hills, NJ, USA, 07078

Website

https://www.humanigen.com

Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005. It has one segment, which is related to the development of pharmaceutical products.

Executives

Dale Chappell	10 percent owner	C/O OPUS EQUUM INC., PO BOX 788, DOLORES CO 81323
Adrian Kilcoyne	officer: Chief Medical Officer	533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010
Cameron Durrant	director	90, FAIRMOUNT ROAD WEST, CALIFON NJ 07830-3330
Edward P. Jordan	officer: Chief Commercial Officer	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
John Hohneker	director	C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Yili Kevin Xie	director	C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146
Black Horse Capital Lp	10 percent owner	C/O OPUS EQUUM INC., PO BOX 788, DOLORES CO 81323
Black Horse Capital Master Fund Ltd.	10 percent owner	C/O OPUS EQUUM, INC., P.O. BOX 788, DOLORES CO 81323
Nomis Bay Ltd.	10 percent owner	C/O EOM MANAGEMENT LTD., ANDREW'S PLACE, 51 CHURCH ST., 5TH FLOOR, HAMILTON D0 HM12
Cheryl Buxton	director	533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010
Cheval Holdings, Ltd.	10 percent owner	P.O. BOX 309G, UGLAND HOUSE, GEORGETOWN, GRAND CAYMAN E9 KY1-1104
Black Horse Capital Management Llc	10 percent owner	C/O OPUS EQUUM INC., PO BOX 788, DOLORES CO 81323
Robert G. Savage	director	C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591
Rainer J. Boehm	director	C/O HUMANIGEN, INC., 1000 MARINA BOULEVARD, SUITE 250, BRISBANE CA 94005-1878
J Gregory Jester	officer: Chief Financial Officer	C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022